- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02889419
Benefits Evaluation of Selfia® Adapted Underwear for MS Patients Performing Self-catheterization (KML)
Benefits Evaluation of Selfia® Adapted Underwear for Multiple Sclerosis Patients With Severe to Moderate Handicap Performing Self-catheterization : a Multicenter, Prospective, Uncontrolled and Before/After Study.
KML is a multicenter, prospective, uncontrolled and before/after study. The study aims to estimate if the use of Selfia ® adapted underwear reduces the necessary duration for the realization of self-catheterisation (SC) for patients affected by multiple sclerosis with severe to moderate disability.
Secondly, the study aims to :
- Estimate the effect of underwear on quality of life, tiredness linked to the act, comfort in the realization of SC, complications with SC, third party intervention ;
- Collect patients' opinion on the use of the underwear SELFIA ® at the end of the 2nd week of evaluation ;
- Measure if the patient reused underwear and if he bought it at 6 months and at 1 year
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Bladder-sphincter disorders affect 80 % of the patients suffering from multiple sclerosis (MS) after 10 years of evolution and urinary self-catheterization (SC) are part of the therapeutic arsenal.
SC involves different steps: the preparation of the material, the undressing, the transfer on toilets, the technical gesture and the dressing. Recommendations of good practice of SC of the French Society of Physical Medicine and Rehabilitation evoke the necessity to adapt the wardrobe but without precision on the definition of this adaptation.
Adapted underwear exists for patients with a disability and is accessible for the general public. However, no clinical trial has ever evaluated their real practical interest for disabled patients realizing SC.
These undergarments, according to our experience, are very ingenious and would bring a real comfort in everyday life from patients with a disability.
In case of SC, this underwear would facilitate and shorten the time dedicated to this technique, especially as SC are realized on average 6 times a day for patients already affected in their movements because of their initial handicap.
The adapted underwear could bring an ease and a speed of dressing / undressing, allow an easier and faster access to the urinary meatus and a limitation of manipulations and mobilizations of the patient allowing an energy saving.
Moreover, disabled patients request concrete advice from health professionals on everyday life problems such as dressing / undressing. Therefore it seemed interesting to estimate the benefits of using adapted underwear for the realization of SC for patients affected by MS with severe to moderate disability (EDSS 6 - 7.5) affecting everyday life activities.
Study Type
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Bordeaux, France, 33076
- Clinique Saint-Augustin
-
Lille, France, 59037
- Hôpital Swynghedauw - CHRU de Lille
-
Lyon, France, 69006
- Cabinet médical de Neurologie
-
Nantes, France, 44093
- Hôpital Saint-Jacques - CHU Nantes
-
Rennes, France, 35043
- Pôle MPR Saint Hélier
-
-
Nord Pas-de-Calais
-
Lomme, Nord Pas-de-Calais, France, 59462
- Groupement des Hôpitaux de l'Institut Catholique de Lille
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with multiple sclerosis (MS) according to McDonald criteria
- At least 18 years old
- Self-catheterization for at least 3 months
- Expended Disability Status Scale (EDSS) between 6.0 and 7.5
- Informed consent
- Coverage of the social insurance
Exclusion Criteria:
- MS relapse in the previous month
- Patient hospitalized in short stay or aftercare departments, no matter the reason
- Morbid obesity (BMI superior to 35)
- Understanding disorders preventing an informed consent
- EDSS inferior to 6.0 or superior to 7.5
- Patient with home bladder catheter
- No capacity to provide a self-catheterisation
- Age under 18 years
- Pregnant or breast-feeding woman
- Patient under legal protection
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Evaluation of underwear Selfia®
Every patient is his own control.
|
Patients are evaluated for a week using their usual underwear for the realization of SC.
At the end of the week, they receive Selfia ® adaptated underwear and they use it for one week for a new evaluation.
Finally, underwear will be given to patients and during follow-up consultations in routine at 6 months and 1 year, he will be asked if they reused or bought underwear.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Average time spend for the realization of a self-catheterisation, from undressing to dressing, measured by a chronometer provided to the patient
Time Frame: 17 days
|
17 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Measure of the quality of life
Time Frame: 17 days
|
Specific scale adapted for the studied population: Qualiveen (self-questionnaire for MS patients with urinary disorders)
|
17 days
|
Measure of fatigue for every SC
Time Frame: 17 days
|
EVA scale
|
17 days
|
Comfort linked to SC
Time Frame: 17 days
|
EVA scale for pain linked to undressing / dressing
|
17 days
|
Consequences from SC complications
Time Frame: 17 days
|
Number of bleeding, EVA scale for the pain linked to the introduction / withdraw of the urinary catheter,
|
17 days
|
Number of documented urinary infections
Time Frame: 17 days
|
17 days
|
|
Number of self-catheterisation or hetero-catheterisation per day
Time Frame: 17 days
|
17 days
|
|
Opinion of the patient (favorable/non favorable) on the use of underwear Selfia ®
Time Frame: at 6 months and at 1 year
|
at 6 months and at 1 year
|
|
Re-use (yes/no) of underwear with or without purchase (yes/no)
Time Frame: at 6 months and at 1 year
|
at 6 months and at 1 year
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Hélène Cattoir-Vue, MD, Groupement des Hôpitaux de l'Institut Catholique de Lille
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RC-P0045
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsActive, not recruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
Queen Mary University of LondonTakeda Pharmaceuticals International, Inc.RecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited Kingdom
-
University of California, San FranciscoUnited States Department of DefenseRecruitingMultiple Sclerosis, Chronic Progressive | Multiple Sclerosis, Relapsing-Remitting | Multiple Sclerosis (MS) | Multiple Sclerosis Relapse | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis Brain Lesion | Multiple Sclerosis BenignUnited States
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Banc de Sang i TeixitsVall d'Hebron Research Institute (VHIR)CompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisSpain
-
BiogenElan PharmaceuticalsCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
Clinical Trials on Evaluation of underwear Selfia®
-
Groupe Mulliez-FloryEVAMEDRecruitingCognitive Impairment | Behavior Disorders | DisorientationFrance
-
Kırıkkale UniversityCompleted
-
Institut National de la Santé Et de la Recherche...Terminated
-
Izmir Bakircay UniversityIstanbul University - Cerrahpasa (IUC)Completed
-
Hacettepe UniversityNot yet recruiting
-
Ankara Yildirim Beyazıt UniversityCompletedType 2 Diabetes Mellitus | BalanceTurkey
-
Federal University of PelotasCompletedObstructive Sleep Apnea Syndrome | Bruxism | Temporomandibular Joint DisordersBrazil
-
Caps Research NetworkCompletedCentral Nervous System SensitizationUnited States, Australia
-
Izmir Bakircay UniversityIstanbul University - Cerrahpasa (IUC)CompletedPulmonary Arterial HypertensionTurkey